A hallmark of obesity‐driven T2D is insulin resistance (Bjorntorp, 1997), and thus, much effort is placed into treatments that promote “insulin sensitisation” (Connor et al, 2015). The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.